The emergence of mephedrone along with other artificial cathinones has introduced troubles for lawmakers and regulatory businesses tasked with controlling the proliferation of latest psychoactive substances. The dynamic character of synthetic drug output, coupled with the flexibility of chemists to change molecular structures to evade lawful limits